APE chemotherapy for children with relapsed Hodgkin disease: A Pediatric Oncology Group trial
- 30 September 2005
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 46 (3) , 320-324
Abstract
Background: MOPP (mechlorethamine, vincristine, procarbazine, prednisone) and ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) are effective therapies for Hodgkin disease (HD) that may cause long‐term toxicities in children. APE (cytosine arabinoside, cisplatin, etoposide) is a non‐cross‐resistant regimen with limited toxicities. We evaluated this regimen for patients with recurrent or refractory disease.Methods: Patients with recurrent Hodgkin disease who were ≤21 years of age and had previously received standard alkylating agent and doxorubicin‐based therapy, were treated with APE chemotherapy (cytosine arabinoside 750 mg/m2, cisplatin 15 mg/m2, etoposide 20 mg/m2) every 12 hr, administered three or four times per cycle. Response, Event‐free survival (EFS), and overall survival (OS) were assessed.Results: Thirty‐one patients in first (n = 25) or second (n = 6) relapse of Hodgkin disease were eligible and evaluable. APE chemotherapy was well‐tolerated, with the major toxicity consisting of short duration, grade 3/4 hematopoietic toxicity. The CR/PR response rate was 68% (42% CR, 26% PR). Allowing subsequent stem cell transplantation in some patients, 4‐year EFS and OS were 27% ± 8% and 49% ± 9%, with 8‐year EFS and OS of 23% ± 9% and 34% ± 10%.Discussion: APE is an efficacious regimen with minimal toxicity. Novel regimens are necessary to: (1) re‐induce remission, (2) treat newly diagnosed patients, and (3) augment therapy in patients with slow response to standard regimens. This regimen had minimal toxicity and an excellent response rate that facilitated long term survival, often in conjunction with transplantation. The Children's Oncology Group is using a similar regimen to augment therapy for slow responders on a current Hodgkin disease trial. Pediatr Blood Cancer.Keywords
This publication has 14 references indexed in Scilit:
- Presalvage prostate‐specific antigen (PSA) and PSA doubling time as predictors of biochemical failure of salvage cryotherapy in patients with locally recurrent prostate cancer after radiotherapyCancer, 2006
- Time-intensified dexamethasone/cisplatin/cytarabine:an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin’s diseaseAnnals of Oncology, 2002
- Randomized Comparison of Low-Dose Involved-Field Radiotherapy and No Radiotherapy for Children With Hodgkin’s Disease Who Achieve a Complete Response to ChemotherapyJournal of Clinical Oncology, 2002
- Outcomes of Treatment of Children and Adolescents With Recurrent Non-Hodgkin’s Lymphoma and Hodgkin’s Disease With Dexamethasone, Etoposide, Cisplatin, Cytarabine, and l-Asparaginase, Maintenance Chemotherapy, and Transplantation: Children’s Cancer Group Study CCG-5912Journal of Clinical Oncology, 2001
- Long‐term follow‐up in patients treated with Mini‐BEAM as salvage therapy for relapsed or refractory Hodgkin's diseaseBritish Journal of Haematology, 2001
- Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factorsBlood, 2000
- Conventional salvage chemotherapy vs. high-dose therapy with autografting for recurrent or refractory Hodgkin's disease patientsAnnals of Hematology, 2000
- ABVD chemotherapy in the treatment of Hodgkin's diseaseCancer Treatment Reviews, 1982
- Asymptotically Efficient Rank Invariant Test ProceduresJournal of the Royal Statistical Society. Series A (General), 1972
- Combination Chemotherapy in the Treatment of Advanced Hodgkin's DiseaseAnnals of Internal Medicine, 1970